Inhibrx Biosciences (INBX) Total Liabilities (2023 - 2025)
Historic Total Liabilities for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $140.6 million.
- Inhibrx Biosciences' Total Liabilities rose 21895.0% to $140.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.6 million, marking a year-over-year increase of 21895.0%. This contributed to the annual value of $47.2 million for FY2024, which is 8215.4% down from last year.
- According to the latest figures from Q3 2025, Inhibrx Biosciences' Total Liabilities is $140.6 million, which was up 21895.0% from $143.6 million recorded in Q2 2025.
- In the past 5 years, Inhibrx Biosciences' Total Liabilities registered a high of $264.4 million during Q4 2023, and its lowest value of $39.1 million during Q2 2024.
- Its 3-year average for Total Liabilities is $118.2 million, with a median of $140.6 million in 2025.
- Per our database at Business Quant, Inhibrx Biosciences' Total Liabilities plummeted by 8215.4% in 2024 and then soared by 26760.99% in 2025.
- Inhibrx Biosciences' Total Liabilities (Quarter) stood at $264.4 million in 2023, then tumbled by 82.15% to $47.2 million in 2024, then skyrocketed by 198.08% to $140.6 million in 2025.
- Its Total Liabilities was $140.6 million in Q3 2025, compared to $143.6 million in Q2 2025 and $148.2 million in Q1 2025.